STOCK MARKET OPENS FOR BIO-UV GROUP
BIO-UV Group, the France-based manufacturer of the BIO-SEA ballast water treatment system and other ultraviolet-based water treatment technologies, has announced its initial public offering (IPO) has been approved on the Paris Euronext Growth market.
The public listing was accepted on the 5th July 2018, with a final share price of €3.84.
The number of shares allocated under the global placement stands at 2,321,430 new shares, representing a total of €8.9 million. 375,380 shares were allocated to the public under the open price offer, for an amount of €1.4 million. BIO-UV Group has a market capitalisation of around €30 million, based on 7,789,295 capital shares.
On completion of the IPO, Benoit Gillmann, CEO and founder of BIO-UV Group, said: “We are proud to announce the success of our IPO and would like to sincerely thank our reference shareholders Soridec, Naxicap and ACE Management for their support, as well as all the new shareholders, institutions and private individuals, who have put their faith in us.
“I would also like to extend my warmest thanks to all the loyal employees of BIO-UV Group, who, through their daily commitment, contribute to the company’s success in France and abroad since nearly 20 years. The funds raised will allow us to accelerate our momentum and seize all opportunities that present themselves, both on our historical markets and the ballast water treatment market, which is set to see major growth.”
Created in 2000, BIO-UV Group designs, manufactures and markets innovative ultraviolet water treatment systems. The range of equipment developed by the Group is aimed at several markets, including the maritime industry.
In 2017, BIO-UV Group generated revenue of €10.2 million and EBITDA of €1.1 million, representing an EBITDA margin of 11.1%.
BIO-UV Group has also been granted the “Innovative Company” label by Bpifrance and is eligible for the French “PEA-PME” investment scheme.
For more information, please contact:
Xavier Deval
Business Director
Ballast Water Treatment Solution
Mobile: + 33(0)6 31 69 69 79
Office: + 33(0)4 99 13 39 11